Role of androgens in normal and pathological ovarian function

K A Walters

Andrology Laboratory, ANZAC Research Institute, Concord Hospital, University of Sydney, Sydney, New South Wales 2139, Australia

Correspondence should be addressed to K A Walters; Email: kwalters@anzac.edu.au

Abstract

Androgens mediate their actions via the androgen receptor (AR), a member of the nuclear receptor superfamily. AR-mediated androgen action is essential in male reproductive development and function; however, only in the last decade has the suspected but unproven role for AR-mediated actions in female reproduction been firmly established. Deciphering the specific roles and precise pathways by which AR-mediated actions regulate ovarian function has been hindered by confusion on how to interpret results from pharmacological studies using androgens that can be converted into oestrogens, which exert actions via the oestrogen receptors. The generation and analysis of global and cell-specific female Ar knockout mouse models have deduced a role for AR-mediated actions in regulating ovarian function, maintaining female fertility, and have begun to unravel the mechanisms by which AR-mediated androgen actions regulate follicle health, development and ovulation. Furthermore, observational findings from human studies and animal models provide substantial evidence to support a role for AR-mediated effects not only in normal ovarian function but also in the development of the frequent ovarian pathological disorder, polycystic ovarian syndrome (PCOS). This review focuses on combining the findings from observational studies in humans, pharmacological studies and animal models to reveal the roles of AR-mediated actions in normal and pathological ovarian function. Together these findings will enable us to begin understanding the important roles of AR actions in the regulation of female fertility and ovarian ageing, as well as providing insights into the role of AR actions in the androgen-associated reproductive disorder PCOS.


Introduction

The androgen receptor (AR) is encoded by a single copy X-chromosomal gene and is a member of the nuclear receptor superfamily (Lubahn et al. 1988, Quigley et al. 1995). The fundamental roles of AR-mediated actions in male reproductive function and many of its disorders are well understood (Quigley et al. 1995). Various clinical observational studies and in vitro pharmacological studies have provided evidence to support the direct involvement of AR-mediated actions in female reproduction (reviewed in Walters et al. (2008, 2010)). However, this has been confirmed only in the last decade using Ar knockout mouse models (ARKO) (Hu et al. 2004, Shiina et al. 2006, Walters et al. 2007, 2009, 2012a, Cheng et al. 2013).

Clinical evidence supporting a direct role for AR-mediated androgen actions in ovarian function comes from the findings that women exposed to androgen excess from endogenous (e.g. congenital adrenal hyperplasia (Lucis et al. 1966, Hague et al. 1990)) or exogenous (testosterone treatment in female-to-male transgender (Pache & Fauser 1993)) sources display polycystic ovaries, supporting a role for androgens in stimulating follicle development. In addition, hyperandrogenism is associated with the female reproductive pathological disorder, polycystic ovary syndrome (PCOS), a common condition causing anovulation and infertility, and associated with an increase in metabolic abnormalities including obesity, insulin resistance, dyslipidaemia, cardiovascular disease and type 2 diabetes (Franks 1995, Pasquali et al. 2010, Goodarzi et al. 2011). Further evidence of a direct role for AR-mediated actions in ovarian function comes from in vitro pharmacological studies, where various androgens, including testosterone, androstenedione (A4) and dihydrotestosterone (DHT), have been reported to enhance follicle growth and development (Murray et al. 1998, Wang et al. 2001), with stimulatory effects blocked by a non-steroidal AR blocker (antagonist; bicalutamide) (Murray et al. 1998). However, conflicting pharmacological findings have been reported regarding apparent androgen effects on ovarian function with ambiguity arising from conversion of androgens into oestrogens, which exert indirect actions via the oestrogen receptor (ER) (Fig. 1A), and...
also because AR antagonists are often mixed partial agonists/antagonists rather than pure blockers.

The development of ARKO mouse models (Yeh et al. 2002, Hu et al. 2004, Shiina et al. 2006, Walters et al. 2007, 2012a, Sen & Hammes 2010, Wu et al. 2014) and PCOS models in rodents (Walters et al. 2012b), sheep (Padmanabhan & Veiga-Lopez 2013) and primates (Abbott et al. 2005) induced by excess androgen exposure provides unique mechanistic insights into the role for AR-mediated androgen actions in ovarian physiology function and the origins of PCOS. This review aims to provide a comprehensive integration of clinical observations with research findings from genetic and pharmacological studies based primarily on whole-animal models, to elucidate the specific roles of AR-mediated androgen actions in regulating normal and pathological ovarian function, and thereby female fertility.

**Androgen biosynthesis and their actions via the AR**

The major circulating steroids relevant to androgen effects in women, in descending order of serum concentrations, are DHEAS, DHEA, A4, testosterone and DHT (Davison & Davis 2003). However, only testosterone and DHT (a pure, non-aromatisable androgen three to ten times more potent than testosterone) bind directly to the AR, while the others are androgen precursors that require conversion to testosterone and/or DHT to exert androgenic effects (Burger 2002). In females, bioactive androgens (testosterone, DHT) are predominantly formed by peripheral conversion (in liver, adipose tissue and skin) of androgen precursors (A4, DHEA and DHEAS) that are secreted from the adrenal glands and the ovaries. DHEA and DHEAS originate predominantly from the adrenal glands (Abraham 1974), while testosterone, DHT and A4 levels ultimately arise equally from the ovary and adrenals (Davison & Davis 2003), apart from mid-cycle when ovarian contribution of A4 is twice that of the adrenal (Abraham 1974). Androgen synthesis and metabolism into other steroids involve a series of pathways and a range of enzymes (Fig. 1B). Androgen synthesis in the ovarian follicle and stroma favours the Δ5-pathway, which involves the conversion of cholesterol into pregnenolone by the enzyme P450 side-chain cleavage (sc, CYP11A1), which is then metabolised to DHEA by P450c17 (CYP17A1) and then A4 by 3β-hydroxysteroid dehydrogenase (3β-HSD), the immediate precursor of testosterone. 17β-HSD can then convert A4 into testosterone, which itself can then be aromatised into oestradiol (E2) by P450arom (CYP19) or reduced to DHT by 5α-reductase 1 (SRD5A1) and 2 (SRD5A2), the latter of which can be enzymatically reduced into 5α-androstene-diols, reversibly into 5α-diol and irreversibly into 3β-diol (Longcope 1986, Miller & Auchus 2011).

Within the ovary, steroidogenesis is compartmentalised in a cell-specific manner, with A4 and testosterone being synthesised in the theca cells, before diffusing into the granulosa cells where they are converted into oestrone (E1) or E2 (Burger 2002, Ghayee & Auchus 2007).

Androgen synthesis within the ovary is under the control of luteinizing hormone (LH), with LH acting via LH receptors on theca cells to stimulate the rate-limiting conversion of cholesterol into pregnenolone (Erickson et al. 1985, Longcope 1986).

Androgens mediate their action primarily via the AR, which resides in the cell cytoplasm in an inactive complex bound to chaperone heat shock proteins, until testosterone or DHT bind to the receptor, which dissociates heat shock protein. The androgen-activated AR can then stimulate transcription of target genes via a sequence of processes, including homodimerisation in an anti-parallel configuration, nuclear translocation, DNA binding, and complex formation with co-regulators and general transcription factors (Quigley et al. 1995). This classical response is termed genomic AR actions as it involves gene transcription. However, androgens are also reportedly capable of non-genomic AR actions, where androgenic actions occur within seconds or minutes after ligand binding, too quickly for nuclear translocation, and the androgenic response is insensitive to inhibitors of transcription or translocation (Foradori et al. 2008).

The molecular basis of non-genomic AR effects, however, remains yet to be fully characterised.

**Pattern of ovarian AR expression**

AR is expressed throughout the hypothalamic–pituitary–gonadal (hpg) axis and the evolutionary conservation of...

AR expression in antral and preovulatory follicles

Strong AR immunostaining is observed in granulosa cells of early rat antral follicles (Szoltys & Slomczynska 2000). During rat antral follicular growth, AR expression progressively declines in the outer mural granulosa cells of later-stage antral follicles, but the cumulus cells surrounding the oocyte maintain strong AR-positive staining (Szoltys & Slomczynska 2000). This gradient of AR expression intensity was also confirmed in mouse antral follicles collected from an in vitro culture system. There the intensity of AR expression increased from the mural granulosa cells to the cumulus cells, and this gradient became more pronounced as antral follicles developed to the preovulatory developmental stage (Lenie & Smitz 2009). Furthermore, following an ovulatory stimulus, cumulus cells exhibit intense AR expression implying that regulation of AR protein expression may be regulated by oocyte-secreted factors (Lenie & Smitz 2009). AR expression is present in granulosa and theca cells of bovine (mRNA: Hampton et al. 2004; protein: Salvetti et al. 2012), ovine (mRNA: Juengel et al. 2006) and porcine (mRNA: Slomczynska et al. 2001; protein: Slomczynska & Tabarowski 2001) antral follicles, with staining most predominant in the granulosa cells. AR protein (Hild-Petito et al. 1991, Hillier et al. 1997) and mRNA (Weil et al. 1998) are expressed in mural granulosa cells and theca cells of primate antral and periovulatory follicles; however, the expression weakens in the granulosa cells as they progress from less mature follicles to periovulatory follicles (Hillier et al. 1997). AR immunostaining is also present in human granulosa and theca cells of antral and preovulatory follicles (Suzuki et al. 1994, Chadha et al. 1994), and AR mRNA and protein are detectable in granulosa cells extracted from human small and large antral follicles (Catteau-Jonard et al. 2008, Nielsen et al. 2011).

AR expression in corpora lutea

AR mRNA is present in primate corpora lutea (CL) (Dufty et al. 1999). During the early luteal phase of a cycle, developing and even regressing primate CL exhibit AR immunostaining (Hild-Petito et al. 1991). However, AR immunostaining is dramatically reduced in fully regressing CL in the early follicular phase of the following cycle (Hild-Petito et al. 1991). AR expression is also

AR expression in the developing ovary

AR is expressed in sheep (Juengel et al. 2006), pig (Burek et al. 2007) and human (Wilson & McPhaul 1996) foetal ovaries. In sheep, AR mRNA and protein is expressed in the stroma, surface epithelium and granulosa and theca cells (Juengel et al. 2006).

AR expression in primordial and primary follicles


AR expression in preantral follicles


Key ovarian defects due to loss of AR as defined by ARKO female models:

- **Preovulatory follicle**
- **Antral follicle**
- **Initiation**
- **Preantral to antral growth**
- **Antral development**
- **Maturation and ovulation**
- **Luteinization**
- **Ovarian function**
- **Ovulation**
- **Corpora lutea**

Figure 2 The pattern of AR expression during follicular development and ovarian defects due to the loss of AR signalling. AR expression is present throughout most stages of follicular development and loss of AR actions in ARKO female mouse models leads to several ovarian defects. E2, oestradiol; LH, luteinizing hormone.

**AR expression in ovarian stroma**

Strong AR mRNA expression is present in ovine ovarian stroma, especially around small growing follicles (Juengel et al. 2006). During the follicular and luteal phases, stroma within primate ovaries exhibits AR protein (Hild-Petito et al. 1991) and mRNA (Weil et al. 1998), and human ovarian stromal cells also express AR protein (Suzuki et al. 1994).

**Insights into the role of AR-mediated actions in ovarian function from clinical studies**

The consistent expression of AR in human ovaries throughout follicular development strongly suggests that it plays a role in regulating ovarian function. Furthermore, increased tissue androgen exposure whether of endogenous androgens in women with congenital adrenal hyperplasia (Lucis et al. 1966), PCOS (Chang 2007) or exogenous testosterone treatment in female-to-male trans-sexuals (Pache & Fauser 1993, Becerra-Fernandez et al. 2014) is associated with a high prevalence of multi-follicular ovaries, supporting a role for androgens in stimulating and then arresting follicle development.

Population studies demonstrate a decrease in circulating blood levels of testosterone, DHEA and A₄ concentrations in women gradually between the ages of 20 and 45 years of age, without specific effects of the menopausal transition (Zumoff et al. 1995, Davison et al. 2005). This decline in pro-androgens and androgens over a woman’s reproductive life may contribute to, or reflect, the diminishing ability of the ageing ovary to respond to follicle-stimulating hormone (FSH)-based stimulation for fertility treatments. Ovarian reserve declines steeply with age, and older women undergoing IVF yield fewer oocytes even after maximal FSH stimulation (Broekmans et al. 2009). In recent years, some IVF centres and individual women have initiated the use of androgen (DHEA or testosterone) pre-treatment for (mainly older) women who exhibit poor ovarian response to FSH stimulation. One recent study has claimed that one-third of all IVF centres worldwide use DHEA supplementation in such women (Gleicher & Barad 2005). Since then, studies using various means to increase androgen exposure (DHEA, testosterone, letrozole) have reported enhanced ovarian response to FSH stimulation (Fabregues et al. 2009), together with increased antral follicle, oocyte and embryo numbers, improved embryo quality and increased pregnancy and live births (Garcia-Velasco et al. 2005, Balasch et al. 2006, Wiser et al. 2010, Kim et al. 2011, Meldrum et al. 2013). However, other studies have failed to confirm these findings using DHEA (Yeung et al. 2014), testosterone (Massin et al. 2006, Sipe et al. 2010) or letrozole (Lossl et al. 2008, Ozmen et al. 2009). A meta-analysis confirmed that transdermal testosterone treatment increased pregnancy and live-birth rates, but there were insufficient data to support a beneficial role for DHEA or letrozole (Bosdou et al. 2012). Another meta-analysis confirmed the lack of sufficient evidence to confirm any beneficial effect of DHEA (Narkwichean et al. 2013). These inconclusive findings are mainly due to study design limitations, notably lack of placebo controls, small sample size, use of aromatisable androgens and inconsistent entry criteria.

In conclusion, clinical studies have provided evidence to support a role for AR-mediated androgen actions on ovarian function. However, despite several lines of evidence supporting a role for androgens in stimulating follicle development and improving ovarian FSH response, the available data from clinical studies remain unconvincing and decisive studies are eagerly awaited.

**Insights into the role of AR-mediated actions in normal ovarian function from animal studies**

**Pharmacological studies**

**Primordial follicle initiation**

Primordial follicle initiation is stimulated in mouse ovaries by testosterone and DHT (Yang et al. 2010), in sheep by DHEA (Narkwichean et al. 2014) and in primates by testosterone and DHT (Vendola et al. 1999a), implying that androgen treatment can promote initiation of primordial follicle growth. Interestingly, this is despite the lack of AR expression in primordial follicles, which indicates that androgen action must be mediated via indirect paracrine mechanisms such as upregulation of insulin-like growth factor 1 (IGF1) and/or its receptor (Vendola et al. 1999a).

**Preantral-to-antral follicle development**

AR-mediated actions are important in the early stages of follicular development. In vitro culture of preantral mouse follicles in the presence of anti-androgen antibodies or an AR antagonist (bicalutamide) significantly suppressed follicle growth and antral cavity development (Murray et al. 1998). In addition, treatment
with DHT restored follicular growth and antral development in follicles with suppressed growth when cultured in a low FSH environment (Murray et al. 1998). Similarly, addition of testosterone, DHT, A4, DHEA or DHEAS to an in vitro culture system enhances mouse preantral follicular development in a dose-dependent manner, with follicles undergoing rapid granulosa cell proliferation and amplified responsiveness to FSH (Wang et al. 2001). These stimulatory effects on follicle development appear not to be due to aromatisation because addition of an AR antagonist (flutamide) blocked the growth effects, and addition of oestrogens (E1 or E2) alone or the presence of an aromatase inhibitor (fadrozole) had no effect on growth (Wang et al. 2001). Similarly, testosterone, but not E2, also stimulates the transition of bovine primary to secondary follicles, an effect blocked by an AR blocker (flutamide). These findings are most consistent with an effect mediated by a direct AR-mediated action, and not indirect effects of aromatisation of testosterone to E2 with subsequent ER-mediated effects (Yang & Fortune 2006). Ten weeks of DHEA treatment in ewes increases the proportion of follicles observed at the antral stage (Narkwichean et al. 2014). Similarly, numbers of growing preantral and small antral follicles are significantly increased in primate ovaries after treatment with either an aromatisable (testosterone) or a non-aromatisable androgen (DHT) (Vendola et al. 1998), and follicle atresia is significantly decreased in vitro with DHT restored follicular growth and antral development rate was due to decreased numbers of granulosa cells per follicle, thus reducing follicular steroidogenesis and leading to lowered circulating E2 levels (Conway et al. 1990). Similarly, in vivo treatment of rats with doses >1 mg of DHT inhibited LH receptor induction in granulosa cells, resulting in absent ovulatory responses to human chorionic gonadotrophin (hCG) treatment (Farookhi 1985). Together, these data imply that optimal levels of androgens are required to maintain normal ovulatory function.

Androgens also play a role in oocyte maturation with testosterone capable of promoting in vitro germinal vesicle breakdown (GVBD) in murine (Gill et al. 2004) and porcine (Li et al. 2008) oocytes. Moreover, in the mouse, these effects appear to be transcription independent as the testosterone-mediated response is suppressed by the addition of AR antagonists (flutamide or hydroxyflutamide), but not the transcriptional inhibitor, actinomycin D (Gill et al. 2004). Conversely, in another study, testosterone inhibited mouse oocyte meiotic maturation and embryonic development in a dose-dependent manner (Anderiesz & Trounson 1995), indicating that testosterone maintains meiotic arrest. Androgen levels appear to be of real importance in the maintenance of oocyte maturation, as elevated levels of A4 and testosterone reduced mouse oocyte meiotic competence (Romero & Smitz 2010). Taken together, these findings show that androgens play a role in the periovulatory stages of follicle development and emphasise that the regulation of oocyte maturation and ovulation are sensitive to the androgenic environment, and that a balance of androgen actions is required for optimal ovarian function. These opposing findings for the role of androgens in the periovulatory stage of follicle development and ovulatory response highlight the need for further mechanistic studies to better elucidate the underlying processes.

Genetic studies

There are many instances of conflicting findings from pharmacological studies investigating specific androgen
effects on follicular development and health. This is mainly due to the conversion of testosterone or A4 into oestrogens, or DHT into 3β-diol, all of which can exert indirect steroidal effects by activating an ER (Fig. 1A). Furthermore, despite the availability of a variety of AR antagonists, this approach is also flawed as steroidal antagonists are usually not pure blockers but may be partial agonists especially when background steroid milieu is weak. Thus, another logical approach to determine the role of AR-mediated actions on ovarian function is provided by the study of female mice homozygous for an inactivated AR (ARKO). Data from these genetic models have complemented, extended and clarified the observations from previous pharmacological approaches and provided definitive proof of a role for AR-mediated actions in the regulation of ovarian function (summarised in Table 1).

Global ARKO

Female ARKO mice cannot be generated by natural breeding owing to obligate paternal sterility of hemizygous males bearing an inactive AR (the classical complete androgen insensitivity syndrome (CAIS), formerly known as testicular feminisation syndrome (tfm)) (Goldstein & Wilson 1972, Notini et al. 2005). In the early 1970s, the first mouse models allowing for analysis of female androgen insensitivity were created. These were the naturally occurring but rare X<sup>Tfm</sup>O female mice (Ohno et al. 1973), and the homozygous Ar<sup>Tfm</sup>/Ar<sup>Tfm</sup> female mice (Lyon & Glenister 1974). X<sup>Tfm</sup>O females displayed ovarian degeneration from ~2 months of age, and although fertility was not quantitatively assessed the authors concluded that AR-mediated actions were essential for normal ovarian function (Ohno et al. 1973). Ar<sup>Tfm</sup>/Ar<sup>Tfm</sup> females did not display similar ovarian failure, with follicles still present in their ovaries at 6 months of age. However, they did exhibit a reduced reproductive lifespan, and their ovaries had fewer primordial follicles and increased follicle atresia, implying accelerated ovarian ageing (Lyon & Glenister 1974, 1980). Hence, presciently using these two models, AR-mediated androgen actions were found to be optimal rather than essential for ovarian function. Data on these two models developed in the 1970s were limited, presumably due to the complex production methods that were inefficient at providing sustainable lines of mice for analysis.

More recently, using a conditional gene-targeting approach, the Cre/loxP system (Kuhn & Torres 2002), global ARKO mice have been created. This approach generates mice that have a targeted deletion of exon(s) of the Ar gene. At present, three distinct female ARKO mouse models have been created with targeted deletions of exon 1 (ARKO<sup>Ex1</sup>, generated using CMV-Cre) (Shiina et al. 2006), exon 2 (ARKO<sup>Ex2</sup>, generated using β-Actin-Cre) (Hu et al. 2004) or exon 3 (ARKO<sup>Ex3</sup>, generated using CMV-or Sox-Cre) (Walters et al. 2007, Cheng et al. 2013) of the Ar gene. Global ARKO males confirmed the complete abolition of classic genomic AR function as they each exhibit all features of the CAIS phenotype (Kato 2002, Yeh et al. 2002, De Gendt et al. 2004, Holdcraft & Braun 2004, Notini et al. 2005).

All of the global ARKO female mouse models are sub-fertile, exhibiting fewer pups/litter (Yeh et al. 2002, Hu et al. 2004, Shiina et al. 2006, Walters et al. 2007) (Table 1). ARKO<sup>Ex2</sup> and ARKO<sup>Ex3</sup> females exhibit abnormal oestrous cycles with the cycles being both longer and irregular (Hu et al. 2004, Walters et al. 2009), indicating that hpg function is defective in the absence of normal AR signalling. Further evidence supporting an extra-ovarian defect in gonadotrophin regulation comes from the findings that ARKO<sup>Ex3</sup> females exhibit a delay in their 1st litter (Walters et al. 2007), and that reduced naturally ovulated oocyte numbers can be overcome by gonadotrophin (pregnant mare serum gonadotrophin/human chorionic gonadotrophin) hyperstimulation (Walters et al. 2007). Additionally, when ARKO<sup>Ex3</sup> or control ovaries are cross-transplanted into ovariectomised control hosts, the control hosts displayed normal oestrous cycles and fertility (percentage of females to produce a litter), whereas transplantation of control ovaries into ovariectomised ARKO<sup>Ex3</sup> hosts led to abnormal oestrous cycles and reduced fertility (Walters et al. 2009). These findings provide direct evidence of a role for extra-ovarian AR-mediated actions in maintaining female fertility. Recent findings have begun to unravel the precise role of AR signalling in neuroendocrine regulation, with ARKO<sup>Ex3</sup> females exhibiting a decreased, and often mistimed, ovulatory LH surge with corresponding reductions in follicular steroidogenesis reflected in decreased serum E<sub>2</sub> and E<sub>1</sub> levels at pro-oestrus (preovulatory stage) (Cheng et al. 2013). Consistent with the observed diminished preovulatory surge, Kiss1 mRNA expression in the anteroventral periventricular nucleus is also reduced in ARKO<sup>Ex3</sup> females (Cheng et al. 2013), implying that AR actions play a role in regulating the control of the kisspeptin/GnRH/LH cascade, which triggers ovulation.

Follicle populations within the ovaries of ARKO mice are normal for at least up to 16 weeks of age (Hu et al. 2004, Shiina et al. 2006, Walters et al. 2007). Older ARKO<sup>Ex1</sup> females exhibited an accelerated depletion of their follicle pool with a complete loss of follicles by 40 weeks of age (Shiina et al. 2006). However, growing follicles at all stages of development are still present in the ovaries of ARKO<sup>Ex3</sup> mice at 52 weeks of age (Walters et al. 2007). Reasons for this discrepancy may be the differences in the way the ARKO models were generated. ARKO<sup>Ex1</sup> and ARKO<sup>Ex2</sup> mouse models exhibit an almost complete loss of the AR protein, while on the other hand, the ARKO<sup>Ex3</sup> model retains a mutant AR protein that may still interact with co-regulators and other transcription factors. Therefore, the premature loss of follicles in the
Table 1 In vivo effects of androgen deficiency defined by distinct global and cell-specific female ARKO mouse models.

<table>
<thead>
<tr>
<th>ARKO mouse model</th>
<th>X^{Tfm}O (Ohno et al. 1973)</th>
<th>ArTfm/ArTfm (Lyon &amp; Glenister 1974)</th>
<th>ARKO&lt;sup&gt;Ex1&lt;/sup&gt; (Shiina et al. 2006)</th>
<th>ARKO&lt;sup&gt;Ex2&lt;/sup&gt; (Yeh et al. 2002, Hu et al. 2004)</th>
<th>ARKO&lt;sup&gt;Ex3&lt;/sup&gt; (Walters et al. 2007, 2009, Cheng et al. 2013)</th>
<th>GCARKO&lt;sup&gt;Ex2&lt;/sup&gt; (Sen &amp; Hammes 2010a)</th>
<th>OoARKO&lt;sup&gt;Ex2&lt;/sup&gt; (Sen &amp; Hammes 2010)</th>
<th>PitARKO&lt;sup&gt;Ex2&lt;/sup&gt; (Wu et al. 2014)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fertility</strong></td>
<td>--</td>
<td>↓ Pups/litter and litters/month</td>
<td>↓ Pups/litter</td>
<td>↓ Pups/litter and litters/month</td>
<td>↓ Pups/litter and litters/ovaries</td>
<td>↓ In cumulative pups/month from 6 months and ↓ litters in 6 months</td>
<td>Normal fertility</td>
<td>↓ Pups/litter</td>
</tr>
<tr>
<td><strong>Oestrous cycles</strong></td>
<td>--</td>
<td>--</td>
<td>↑ Oestrous cycle length</td>
<td>↑ Oestrous cycle length, irregular oestrous cycles</td>
<td>↑ Oestrous cycle length at 6 months but not 2 months</td>
<td>↑ Oestrous cycle length at 6 months but not 3 months</td>
<td>Normal oestrous cycles</td>
<td>Trend to ↑ time at oestrus</td>
</tr>
<tr>
<td><strong>Serum steroids and hormones</strong></td>
<td>--</td>
<td>No change in FSH, LH, E&lt;sub&gt;2&lt;/sub&gt;, testosterone at dioestrus.</td>
<td>↓ LH, E&lt;sub&gt;2&lt;/sub&gt; and E&lt;sub&gt;1&lt;/sub&gt; at pro-oestrous.</td>
<td>↑ LH after Ovx. Normal LH response to GnRH and Ovx + E&lt;sub&gt;2&lt;/sub&gt;</td>
<td>No change in FSH or LH at dioestrus.</td>
<td>No change in FSH or LH at dioestrus.</td>
<td>--</td>
<td>↓ FSH at all oestrous cycle stages. ↓ LH but no change in E&lt;sub&gt;2&lt;/sub&gt; or testosterone at pro-oestrous. Normal LH response to GnRH. ↓ LH and FSH after Ovx and Ovx + E&lt;sub&gt;2&lt;/sub&gt;</td>
</tr>
<tr>
<td><strong>Ovarian morphology</strong></td>
<td>Ovaries show signs of deterioration</td>
<td>Ovaries normal in appearance</td>
<td>Ovaries and oviducts normal in appearance</td>
<td>Ovaries and oviducts normal in appearance</td>
<td>Ovaries and oviducts normal in appearance</td>
<td>Ovaries normal in appearance</td>
<td>Ovaries normal in appearance</td>
<td>Ovaries normal in appearance</td>
</tr>
<tr>
<td><strong>Follicle populations</strong></td>
<td>↓ Primordial at 6 months</td>
<td>Growing follicle populations normal at 8 weeks. Total follicle exhaustion by 40 weeks.</td>
<td>Growing follicle populations normal at 4 and 16 weeks. ↓ CL</td>
<td>Growing follicle populations normal at 10–12, 26 and 52 weeks. ↓ CL. At dioestrus growing follicles populations normal at 8 weeks. Total follicle exhaustion by 40 weeks. ↓ CL</td>
<td>Growing follicle populations normal at 4 weeks. At 2 and 6 months ↑ preantral follicles, but ↓ antral follicles and CL, followed by premature ovarian failure</td>
<td>At dioestrus no difference in follicle populations. ↓ CL</td>
<td>Growing follicle populations and CL normal</td>
<td>At dioestrus no difference in follicle populations. ↓ CL</td>
</tr>
<tr>
<td><strong>Follicle growth</strong></td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>No change in granulosa or theca cell proliferation rates</td>
<td>--</td>
<td>No difference in follicle populations at 6 months</td>
<td>--</td>
<td>--</td>
</tr>
</tbody>
</table>

(continued)
### Table 1 (Continued)

<table>
<thead>
<tr>
<th>ARKO mouse model</th>
<th><strong>X&lt;sup&gt;Tm&lt;/sup&gt;O</strong> (Ohno et al. 1973)</th>
<th><strong>Ar&lt;sup&gt;Tfm&lt;/sup&gt;/Ar&lt;sup&gt;Tfm&lt;/sup&gt;</strong> (Lyon &amp; Glenister 1974)</th>
<th><strong>ARKO&lt;sup&gt;Ex1&lt;/sup&gt;</strong> (Shiina et al. 2006)</th>
<th><strong>ARKO&lt;sup&gt;Ex2&lt;/sup&gt;</strong> (Walters et al. 2007, 2009, Cheng et al. 2013)</th>
<th><strong>GCARKO&lt;sup&gt;Ex2&lt;/sup&gt;</strong> (Sen &amp; Hammes 2010)</th>
<th><strong>OoARKO&lt;sup&gt;Ex2&lt;/sup&gt;</strong></th>
<th><strong>PitARKO&lt;sup&gt;Ex2&lt;/sup&gt;</strong> (Wu et al. 2014)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oocyte and follicle health</strong></td>
<td>Oocyte deterioration</td>
<td>Atretic follicles</td>
<td>Atretic follicles</td>
<td>Granulosa cell thickness in antral follicles. Follicular atresia after hyper-stimulation. Dissociation of cumulus cells from oocyte in preovulatory follicles</td>
<td>Unhealthy follicles. No dissociation of cumulus cells from oocyte in preovulatory follicles</td>
<td>Unhealthy follicles and ZPR counts at 6 months</td>
<td>Pyknotic granulosa cells in antral follicles</td>
</tr>
<tr>
<td><strong>Ovulation</strong></td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Naturally ovulated oocytes. Supernovulated ovulation rates normal</td>
<td>Cumulus expansion</td>
<td>–</td>
</tr>
<tr>
<td><strong>Embryo development</strong></td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>No change in fertilisation or progression to 2-cell stage</td>
<td>Rate of fertilisation</td>
<td>–</td>
</tr>
<tr>
<td><strong>Luteinisation</strong></td>
<td>Ovaries show signs of precocious luteinisation</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td><strong>Ovarian gene expression</strong></td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>At pro-oestrus ↓ Kirk, Bmp15, Gdf9, Hgf, but no change in Lhr, Fsh, Cyp11a1, Cyp17a1, Cyp19a1, Es2, Ccdn2 or Igf1. No change in Pgs2 or Pgr at oestrus</td>
<td>↓ Fshr and Igfr at 10 days of age. After hyper-stimulation ↓ Pgr, Has2, Tsg6, p27, Cyp11a1 and ↑ Cyp17a1, but no change in Cyp19a1</td>
<td>No change in Bax, Bcl2, Srd5a1, Srd5a2, Hsd3b1 and Akr1c14 at dioestrus. At oestrus Cyp19a1 ↓, but Star, Cyp17a1 and Cyp17a1 unchanged</td>
<td>No change in Kitl, Igfr1 or Fshr at dioestrus</td>
</tr>
</tbody>
</table>

*Tim*, testicular feminisation syndrome; *Fsh*, follicle-stimulating hormone receptor; *Lhr*, luteinizing hormone receptor; *E<sub>2</sub>*, oestradiol; *P<sub>4</sub>* progesterone; *E<sub>1</sub>* oestrone; *GnRH*, gonadotrophin-releasing hormone; *OVX*, ovariectomy; *CL*, corpora lutea; *ZPR*, zona pellucida remnants; *DHT*, dihydrotestosterone; *GVBD*, germinal vesicle breakdown; *Kitl*, KIT ligand; *Bmp15*, bone morphogenetic protein 15; *Gdf9*, growth differentiation factor 9; *Hgf*, hepatocyte growth factor; *Cyp11a1*, cholesterol side-chain cleavage cytochrome P450; *Cyp17a1*, 17α-hydroxylase/C17-20 lyase cytochrome P450; *Cyp19a1*, aromatase cytochrome P450; *Ccnd2*, cyclin D2; *Igf1*, insulin-like growth factor 1; *Igf1r*, insulin-like growth factor 1 receptor; *Pgs2*, cyclo-oxygenase 2; *Pgr*, progesterone receptor; *Has2*, hyaluronan synthase 2; *Tsg6*, tumour necrosis factor α-stimulate gene 6; *Bax*, Bcl2-associated X protein; *Bcl2*, B cell leukaemia/lymphoma 2; *Srd5a1*, 5α reductase type 1; *Srd5a2*, 5α reductase type II; *Hsd3b1*, 3β-hydroxysteroid dehydrogenase; *Akr1c14*, 3α-hydroxysteroid dehydrogenase; *Star*, STAR protein.
AKOEx2 mouse model may be the consequence of secondary effects of the near-total loss of AR protein, which may disrupt other pathways beyond that of AR transcriptional activity, such as co-regulator interactions.

Direct intra-ovarian effects arising from absent AR action are also evident, with follicle development compromised in all ARKO model ovaries. Follicular atresia is significantly increased in all ARKO mouse models (Yeh et al. 2002, Hu et al. 2004, Shiina et al. 2006, Walters et al. 2007). Reduced follicle health, defined by the presence of degenerate oocytes and/or >10% pyknotic granulosa cells, and impaired antrum development were apparent in antral follicles (Walters et al. 2007, Cheng et al. 2013) in the ARKOEx3 model, and granulosa cell thickness was significantly reduced in ARKOEx2 antral follicles (Hu et al. 2004). Ovarian Fsh and ltf expression levels, both key regulators of follicle development, are significantly reduced in ARKOEx2 mice (Hu et al. 2004), and oocyte/follicle diameter ratios are reduced in small antral follicles of ARKOEx3 mice, indicating an altered pattern of follicle growth (Cheng et al. 2013). In addition, preovulatory follicle numbers, at the pro-oestrous stage, within the ovaries of ARKOEx3 mice are significantly reduced (Cheng et al. 2013). Taken together, these finding imply that AR actions help maintain (or provide necessary support) late follicle development, and disruption of AR signalling leads to dysfunctional late follicle health and fewer follicles developing to the preovulatory stage.

Oocyte health and cumulus cell function are impaired during the final stages of follicle development with ARKOEx2 oocytes in preovulatory follicles exhibiting a loss of cumulus cell contact during ovulation. On the other hand, in the ARKOEx3 model, which retains non-functional AR protein, preovulatory follicles exhibit no disassociation of cumulus cells from their oocytes (Walters et al. 2008), and ARKOEx3 embryo quality is unaffected with normal embryonic development to the blastocyst stage (Walters et al. 2007, Cheng et al. 2013). These findings imply that AR actions may influence oocyte and follicle health via mechanisms independent of direct DNA-binding-mediated transcription. Indeed, in the mouse, testosterone induces in vitro GVBD of mouse oocytes by transcription-independent mechanisms (Gill et al. 2004). AR signalling is essential for optimal oocytic viability, as the key finding from all ARKO female models was that they exhibited a significant reduction in the numbers of CL (Hu et al. 2004, Shiina et al. 2006, Walters et al. 2007, Cheng et al. 2013). The body of evidence from the ARKO models indicates that the observed reduction in ovulation rates in ARKO females is due to a combination of dysfunctional late oocyte/follicle heath, the development of fewer preovulatory follicles and reduced preovulatory E2 and LH levels.

In conclusion, data from the three global ARKO mouse models have confirmed that both extra- and intra-ovarian AR-mediated actions play a role in maintaining normal ovarian function and female fertility. AR actions appear to have a positive role in follicle development, particularly during the later stages of follicle development where AR is involved in ovulation priming by regulating gonadotrophin secretion, and also maintaining antral follicle health and promoting preovulatory follicle development.

**Global heterozygous ARKO**

Limited data are available from two ARKO+/− female mouse models on the effect of AR haploinsufficiency on female fertility and ovarian function. For up to 6 months of age, ARKOEx2+/− and ARKOEx3+/− females display normal fertility (Hu et al. 2004, Walters et al. 2007). However, ARKOEx3+/− females exhibit an age-dependent reduction in pups per litter evident from 6 months of age, indicating a significant Ar gene dosage effect on female fertility (Walters et al. 2007). ARKOEx3+/− ovaries display normal growing follicle populations and follicular health, but a significant reduction in CL counts at 3 and 6 months of age (Walters et al. 2007). The number of oocytes collected after natural ovulation (Walters et al. 2007) and hyperstimulation (Hu et al. 2004, Walters et al. 2007) was not reduced in either ARKOEx2+/− and ARKOEx3+/− females, implying that the reduced CL numbers are due to defective CL formation and/or maintenance rather than reduced ovulation rates. Haploinsufficiency of the inactivated AR also has no effect on oocyte viability with ARKOEx3+/− oocytes exhibiting normal fertilisation rates and progression to the two-cell stage (Walters et al. 2007). Interestingly, partial loss of AR action in granulosa cells, as observed in the heterozygous GCARKOEx2+/− females, has no effect on fertility, oestrous cycles or ovarian morphology (Sen & Hammes 2010).

In summary, findings from the two ARKO+/− female mouse models have revealed a gene dosage effect of AR on female fertility, with a fully functional AR required for optimal female fertility.

**Granulosa cell-specific ARKO**

Two distinct granulosa cell-specific ARKO (GCARKO) mouse models have been reported in female mice (Sen & Hammes 2010, Walters et al. 2012a). These models aimed to achieve complete AR inactivation in granulosa cells but normal AR function in all other cells using the granulosa cell promoters Amhr2 (Sen & Hammes 2010) and Amh (Walters et al. 2012a) to cause a deletion of exon 2 (GCARKOEx2) (Sen & Hammes 2010) and an in-frame deletion of exon 3 (GCARKOEx3) (Walters et al. 2012a). AR mRNA and protein were absent in granulosa cells from the ovaries of GCARKOEx2 mice (Sen & Hammes 2010); however, nonspecific leakage expression of the Amhr2-Cre promoter has been detected in the uterus, oocyte and theca cells (Jorgez
et al. 2004, Hernandez Gifford et al. 2009, Sen & Hammes 2010), inferring that while the phenotype of the GCARKO<sup>Ex2</sup> mouse model may be primarily due to the loss of AR signalling within the granulosa cells, loss of AR action in non-granulosa cells of the reproductive tract may contribute to the phenotype. In the GCARKO<sup>Ex3</sup> mouse model, PCR and lacZ staining analysis confirmed the excision of Ar exon 3 was located only in the granulosa cells, and not the oocyte, theca cells, uterus, brain or pituitary (Walters et al. 2012a). Strong AMH-Cre expression was observed in large preantral and antral follicles, consistent with AMH expression patterns, while expression was lower or undetectable in granulosa cells of primordial, primary and small preantral stages (Walters et al. 2012a). Thus, in the GCARKO<sup>Ex3</sup> model, as not all granulosa cells exhibited the excised exon 3 of Ar, the observed findings may be an underestimation of the importance of granulosa cell AR actions on ovarian function, and thus female fertility.

Both GCARKO female mouse models are sub-fertile (Sen & Hammes 2010, Walters et al. 2012a). GCARKO<sup>Ex2</sup> females exhibit a reduction in pups per litter and total litters from 2 months of age (Sen & Hammes 2010), while GCARKO<sup>Ex3</sup> females display a reduction in total litters over 6 months and an age-dependent reduction in the total number of pups born, evident from 6 months of age (Walters et al. 2012a). Oestrous cycles in both GCARKO models were normal at 2 and 3 months of age but significantly longer by 6 months of age, implying that the loss of AR granulosa cell AR actions may alter hpg feedback signalling (Sen & Hammes 2010, Walters et al. 2012a).

Follicle dynamics are altered by the loss of granulosa cell AR function. Ovaries of GCARKO<sup>Ex2</sup> mice exhibit an increase in preantral follicles, but a decrease in antral follicles and CL from 2 months of age, followed by premature ovarian failure (Sen & Hammes 2010). While ovaries of GCARKO<sup>Ex3</sup> mice display a reduction in large preantral and small antral follicles at 3 months of age, but no difference in follicle populations at 6 months of age, or CL numbers at 3 and 6 months of age (Walters et al. 2012a). The observed reduction in the number of growing follicles at later stages of development supports the notion of AR having a stimulatory role in normal follicle development. The presence (GCARKO<sup>Ex2</sup>) or absence (GCARKO<sup>Ex3</sup>) of accelerated follicle depletion in the GCARKO models corresponds to their respective global ARKO models. Hence, the discrepancy in the findings appears to be due to the complete loss of AR protein in the GCARKO<sup>Ex2</sup> model, compared with the maintenance of a mutant AR protein in the GCARKO<sup>Ex3</sup> model. A role for AR in regulating granulosa cell survival and thus protecting the follicle from undergoing follicular atresia is supported by both GCARKO models, which displayed significant reductions in follicle health (Sen & Hammes 2010, Walters et al. 2012a). As shown in the global ARKO models, dysfunction ovulation was a key feature of the GCARKO<sup>Ex2</sup> model, with females displaying reduced CL numbers and naturally ovulated oocyte numbers (Sen & Hammes 2010). However, in contrast, GCARKO<sup>Ex3</sup> females had normal numbers of naturally ovulated oocytes but reduced cumulus expansion and oocyte/embryo viability, displayed by decreased fertilisation rates and progression to the two-cell stage (Walters et al. 2012a). Thus, granulosa cell AR actions appear to be important in numerous stages of the periovulatory phase.

In summary, the GCARKO female mouse models have demonstrated that within the ovary granulosa cells is an important site for AR actions, involved in maintaining normal follicle development and optimal female fertility. In particular, these data support a stimulatory role of granulosa cell AR-mediated androgen action on follicle development and a maintenance role during the periovulatory phase.

**Oocyte cell-specific ARKO**

One oocyte cell-specific ARKO (OoAR KO) has been created by crossing the GDF9-Cre promoter-driven Cre line with the exon 2-floxed Ar (Sen & Hammes 2010). Ar mRNA analysis identified that Ar expression, while still present, was significantly reduced (approximately fourfold) in OoAR KO denuded oocytes compared with control females (Sen & Hammes 2010). Hence, observed findings may undervalue the contribution of oocyte AR actions in ovarian function. OoAR KO females were reported to have normal fertility, oestrous cycles, follicle populations and CL numbers at 2 months of age (Sen & Hammes 2010). However, oocyte maturation (GVBD) induced in vitro by a high concentration of the aromatisable androgen, DHT, was significantly reduced in OoAR KO oocytes. These findings imply that while AR oocyte actions are not essential for overall ovarian function and female fertility, they may play an important role when intra-ovarian levels of androgens are elevated, such as in women with PCOS (Sen & Hammes 2010).

In conclusion, AR inactivation in the oocyte, as shown in the one OoAR KO female mouse model, appears to have no major overall effect on female fertility; however, low Ar mRNA levels were still present and the presence of AR protein was not analysed, hence the effects of oocyte-specific AR actions may be underestimated in this mouse model.

**Pituitary-specific ARKO**

Recently, a pituitary-directed ARKO (PitAR KO) has been created by crossing the α subunit of gonadotrophins (αGSU)-Cre promoter-driven Cre line with the exon 2-floxed Ar (Wu et al. 2014). As this pituitary glycoprotein alpha subunit is common to TSH as well as LH and FSH, targeting of the common α subunit would involve thyrotrophs as well as gonadotrophs and its inactivation produces hypothyroidism as well as...
gonadotrophin deficiency (Kendall et al. 1995). Deletion of Ar in those pituitary cells in this mouse model reduced Ar mRNA levels by 50%, as well as AR protein levels in PitARKO pituitaries compared with control, while AR expression was unaffected in the hypothalamus, ovary and liver (Wu et al. 2014). PitARKO females displayed normal oestrous cycles but were sub-fertile producing fewer pups per litter (Wu et al. 2014). Growing follicle populations were normal but antral follicle health was reduced and there were fewer CL (Wu et al. 2014), as observed in global (Hu et al. 2004, Shiina et al. 2006, Walters et al. 2007) and GCARKOEx2 (Sen & Hammes 2010) mouse models, indicative of reduced ovulation rates. PitARKO females exhibited significantly reduced FSH levels at pro-oestrus (Wu et al. 2014) and, as observed in the global ARKOEx3 model (Cheng et al. 2013), reduced ovulatory LH levels (Wu et al. 2014), confirming that AR signalling in the pituitary plays an important role in maintaining optimal ovulatory surge levels.

In summary, AR inactivation in some pituitary cells confirms a neuroendocrine role for AR-mediated actions in the regulation of female fertility, notably involving optimising ovulation, although the contribution of the concomitant hypothyroidism (Dittrich et al. 2011) to the features in this model remains to be evaluated.

Androgen–AR mediated molecular mechanisms controlling ovarian physiology

There is limited understanding of the underlying mechanisms of AR-mediated androgen regulation of follicular dynamics. However, testosterone and DHT promote primordial follicle activation in mouse neonatal ovaries via the phosphatidylinositol 3-kinase (PI3K)/Akt/ Forkhead box 3a (Foxo3a) pathway (Yang et al. 2010). Additionally, testosterone and DHT also promote growth initiation of non-human primate primordial follicles, thought to be mediated by upregulation of IGF1R-mediated actions in primordial follicle oocytes (Vendola et al. 1999a). Several studies have indicated that androgens can synergise with FSH, with DHT enhancing FSH-mediated mouse preantral-to-antral follicular growth (Sen et al. 2014) and FSH-stimulated proliferation in porcine cumulus cells (Hickey et al. 2004), testosterone increasing FSH responsiveness in mouse preantral follicles (Wang et al. 2001) and Δ4 increasing FSH-dependent E2 secretion in bovine granulosa cells (Hamel et al. 2005). Pre-treatment with testosterone is reported to significantly reduce the duration of FSH ovarian stimulation and lower the total FSH dose administered to IVF patients, with the FSH-sparing effect of testosterone presumably due to improving ovarian sensitivity to FSH (Fabregues et al. 2009). Androgens appear to enhance FSH ovarian actions, as testosterone increases FSHR mRNA expression in primate primary follicles (Weil et al. 1999) and DHT increases FSHR expression in porcine preovulatory follicles (Cardenas et al. 2002). Interestingly, in mice, DHT and testosterone increase FSHR protein (but not mRNA) expression (Sen et al. 2014). This increase was blocked by the AR antagonist flutamide, a MEK inhibitor, and paxillin siRNA – with paxillin being a mediator between non-genomic and genomic transcription – thus, implying that the increase in FSHR protein expression was via non-genomic AR-driven transcription mechanisms (Sen et al. 2014).

Apart from the synergistic effects of androgens with FSH, DHT can enhance the proliferation of porcine granulosa cells by IGF1 alone or GDF9 in the presence of IGF1 (Hickey et al. 2004, 2005), with these effects reversed by the addition of an AR antagonist. Direct AR effects also promote the differentiation of rat granulosa cells, with testosterone acting via the AR increasing aromatase and CYP11A1 mRNA and protein expression levels via an increase in liver receptor homologue 1 (NR5A2) (Wu et al. 2011), which is expressed in most steroidogenic tissues and regulates the expression of several steroid-metabolising enzymes. In addition, DHT, but not in the presence of the AR antagonist flutamide, reduces connexin43 (CXA1) expression in human granulosa cells in vitro, thus implying that AR-mediated actions may regulate follicle development by regulating gap junctional communication. AR-mediated actions are implicated in the regulation of ovariolytic processes, with DHT inducing the expression of cyclo-oxygenase 2 and amphiregulin in rodent periovulatory granulosa cells (Yazawa et al. 2013). A loss of AR signalling leads to a reduction in expression of hyaluronan synthase 2 and tumour necrosis factor a-stimulated gene 6 in the ovaries of ARKOEx2 mice, both of which are required for normal cumulus expansion (Hu et al. 2004). In addition, at the preovulatory stage (pro-oestrus), gene expression levels of KIT ligand, bone morphogenetic protein 15 and growth differentiation factor 9, all involved in the oocyte–granulosa cell regulatory loop, are reduced in the ovaries of ARKOEx1 mice (Shiina et al. 2006).

Androgens indirectly protect the follicle from atresia by acting as the essential substrate for the follicle survival factor E2 and augmenting the FSH responsiveness of granulosa cells in a developmental stage-dependent manner (Harlow et al. 1988). However, androgens can also directly influence follicle atresia with testosterone and DHT, inducing oocyte degeneration, granulosa cell pyknosis and somatic cell atresia in hypophysectomised rats (Hiller & Ross 1979, Azzolin & Saiduddin 1983), and inappropriate exposure of testosterone to immature murine oocytes leading to a reduced capacity for them to mature and undergo normal embryonic development (Anderiesz & Trounson 1995). A loss of AR signalling, as shown in ARKO mouse models, also increased levels of follicular atresia, revealing that a balance in AR actions is necessary for optimal follicle health (Hu et al. 2004,
Shiina et al. 2006, Walters et al. 2007, 2012a, Sen & Hammes 2010, Cheng et al. 2013). Furthermore, an androgenic mechanism for attenuating follicular atresia has been revealed with testosterone and DHT, but not E2, increasing granulosa cell expression of microRNA-125b (Sen et al. 2014), which suppresses proapoptotic protein (BAK1, BMX, BMF and TRP53) expression (Shi et al. 2007, Sen et al. 2014). This upregulation is mediated via non-genomic androgen-induced matrix metalloproteinase (MMP)-mediated transactivation of membrane-bound epidermal growth factor receptor (EGFR), triggering MAPK3/1 signalling in the cytoplasm as required for genomic Ar transcriptional effects. In addition, the scaffold protein paxillin, required for AR nuclear localisation in granulosa cells (Sen et al. 2012), has been identified an essential mediator of non-genomic and genomic AR signalling, which in turn regulates miR-125b expression in granulosa cells (Sen et al. 2014).

In summary, while only a few target genes, so far, have been shown to be regulated by AR activation in the ovary, it is clear that AR-mediated activity plays an important role in the augmentation of several key regulators of follicle growth and health, through all stages of follicle development.

**Human implications in the role of AR-mediated actions in normal ovarian function from clinical and animal studies**

A large number of clinical, pharmacological and ARKO studies imply that AR signalling enhances follicle development by stimulating growth, maintaining health and increasing the response of the ovary to FSH with obvious implications for women undergoing assisted reproductive techniques (ARTs). Recent studies have highlighted potential beneficial effects on antral follicle, oocyte and embryo numbers, embryo quality, and pregnancy and live birth rates, of treating women who have had a poor ovarian response with pre-treatments that elevate androgen exposure. In addition, the findings that AR expression remains intense in the cumulus cells of preovulatory follicles (Szoltys & Slomczynska 2000, Lenie & Smitz 2009), and loss of AR signalling in granulosa cells impaired cumulus expansion and reduced oocyte/embryo viability (Walters et al. 2012a), imply a key role for AR actions in late stages of oocyte maturation and warrant investigations into the use of androgens in *in vitro* maturation (IVM) culture systems.

When depletion of the follicular pool falls below a critical threshold, menopause ensues. Thus, the functional lifespan of the ovary and hence the age of menopause are largely dictated by the rate of follicle atresia (Richardson 1993). As all global (Hu et al. 2004, Shiina et al. 2006, Walters et al. 2007, Cheng et al. 2013) and granulosa cell-specific (Sen & Hammes 2010, Walters et al. 2012a) ovaries of ARKO mice display increased follicular atresia, it is likely that AR signalling influences the rate of follicle atresia. Moreover, ARKOEx3 females exhibit an accelerated depletion of their follicle pool and complete ovarian failure by 40 weeks of age (Shiina et al. 2006). Premature ovarian failure (POF) is characterised in women by the premature depletion of follicles before the age of 40 years and has been linked with abnormalities involving X-linked genes (Persani et al. 2010). AR is located on the X chromosome and alterations in the polymorphic CAG repeat located on exon 1 (Xq11-12) of the Ar gene have been suggested as a possible susceptibility factor for the development of POF (Sugawa et al. 2008, Laisk et al. 2010); however, further evidence is required to support this association. To date, no evidence has been published describing the prevalence of inactivating AR mutations in women with POF (Persani et al. 2010). Furthermore, the fact that the complete loss of follicles was not observed in the ARKOEx3 mouse model (Walters et al. 2007), which retains a non-functional protein, implies that genomic AR activation does not play an essential role in follicle depletion.

Although females homozygous for an inactivated AR cannot occur naturally in women, the finding that ARKOEx3 +/- female mice exhibit an age-dependent reduction in fertility entails a gene dosage effect of Ar on determining female fecundity (Walters et al. 2007). This may have implications for the reproductive performance of mothers of males with CAIS who are obligate heterozygotes of CAIS AR mutations, as it predicts that these women may exhibit a reduced reproductive lifespan and/or protection against hyperandrogenic disorders such as PCOS. Clinical studies examining these predictions would be of great interest.

**Insights into the role of AR-mediated actions in PCOS from clinical studies**

PCOS is a common endocrine condition affecting 5–10% of women of reproductive age (Franks 1995). It is characterised by reproductive, endocrine and metabolic features including anovulation, infertility, hyperandrogenism, obesity, hyperinsulinism and an increased risk of type 2 diabetes and cardiovascular disease (Fauser et al. 2012). This review will outline the evidence supporting a role for AR actions in the development of traits of PCOS, with the main focus being on reproductive and endocrine features, which lead to the dysfunctional ovarian function observed in many patients with PCOS. Reduced fertility is a key feature of PCOS, caused by arrested follicular maturation, dysfunctional ovulation and an increased risk of gestational diabetes, pre-eclampsia, pre-term birth and miscarriage (Tandulwadkar et al. 2014). Patterns of reproductive hormone release are also altered, with
PCOS women exhibiting LH hypersecretion and hyperandrogenism. Highlighting the phenotypic heterogeneity of the condition, there are at present three clinical definitions used to classify PCOS in women. In 1990, the National Institute of Child Health and Human Development Conference recommended that the diagnostic criteria, in the order of importance, should be defined as hyperandrogenism, menstrual dysfunction and the exclusion of other known factors (Zawadski & Dunai 1992). Subsequently, the 2003 Rotterdam consensus criteria were formulated to require for diagnosis two out of the following three criteria: oligo-ovulation or anovulation, hyperandrogenism and polycystic ovaries (Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 2004). A diagnosis of polycystic ovaries is based on morphological criteria obtained from ultrasonographic data, where ovaries are observed to be enlarged and exhibit more than 12 follicles per ovary with a diameter of 2–10 mm, a thickened outer tunica albuginea, and an increased density and area of stroma (Takahashi et al. 1994, Franks 1995, Chang 2007). This definition for PCOS was followed in 2006 by the Androgen Excess PCOS Society’s recommended diagnostic criteria of the presence of hyperandrogenism, and/or oligo-ovulation and polycystic ovaries, and the exclusion of other related disorders (Azziz et al. 2006, 2009). Unity has still not been reached on the diagnostic criteria for PCOS, with recent recommendations that metabolic disorders be added when defining the PCOS phenotype (Conway et al. 2014). Nevertheless, the most consistent feature of PCOS is hyperandrogenism, affecting at least 60% of women with PCOS (Abbott et al. 2005, Livadas et al. 2014), highlighting the importance of androgenic actions in the disorder.

Despite substantial research, the origins and underlying mechanisms of PCOS remain unclear. However, numerous lines of clinical evidence implement AR-mediated actions as playing an important, if not essential, role in the development and maintenance of PCOS. Serum levels of various androgens (testosterone, A₄ and DHEAS) and the enzyme 3β-HSD (required in the pathway to convert pro-androgens into bioactive androgens) are consistently elevated in PCOS patients compared with controls (Keele et al. 2014, Palomba et al. 2014). High levels of androgen exposure caused by endogenous adrenal androgen hypersecretion in congenital adrenal hyperplasia (Lucis et al. 1966, Hague et al. 1990) or exogenous testosterone treatment in female-to-male trans-sexuals (Futterweit & Deligdisch 1986, Spinder et al. 1989, Pache & Fauser 1993) induces the ovarian PCOS traits of enlarged, multi-cystic ovaries and theca interstitial hyperplasia, implicating androgens in the development of the PCOS ovarian phenotype. Furthermore, elevated androgen secretion in vitro by human theca interna cells excised from PCOS ovaries has been reported, with theca cells producing 20 times more A₄ than those from normal ovaries (Gilling-Smith et al. 1994), with this feature persisting over the entire period of long-term culture (Nelson et al. 1999).

Consistent with a direct role for AR-mediated androgen actions in the etiopathogenesis of PCOS, treatment with the AR antagonist flutamide restores menstrual regularity and ovulation in some PCOS patients (Rittmaster 1999, Paradisi et al. 2013). Furthermore, a role for AR-mediated androgen actions in the neuroendocrine dysfunction observed in PCOS women is supported by the finding that blockade of androgen actions by flutamide restored the reduced sensitivity of the GnRH pulse generator to feedback inhibition by E₂ and P₄ (Eagleson et al. 2000).

An increase in AR activity at the level of the ovary, hypothalamus or potentially the adipocyte or skeletal muscle has been proposed as a possible mechanism involved in PCOS pathogenesis (Baculescu 2013). Some studies have linked alterations in the length of CAG repeats within exon 1 of the AR with changes in the activity of AR (Chamberlain et al. 1994, Choong et al. 1996, Simanainen et al. 2011), and several studies have reported an association between variations in the length of CAG repeats and the prevalence of PCOS (reviewed in Baculescu (2013)). However, the incidence of PCOS has been associated with both short (Mifsud et al. 2000, Schuring et al. 2012) and long (Hickey et al. 2002) CAG repeat lengths in different sub-populations, and other studies show no difference in CAG repeat length between PCOS patients and controls (Kim et al. 2008, Skrgatic et al. 2012). Inconsistencies in these findings may be explained by variability in diagnostic criteria and/or differences in ethnic backgrounds as well as chance findings where no relationship exists. Hence, a role for alterations in AR-mediated transcriptional activity, due to the CAG repeat polymorphism, in the prevalence of PCOS is yet to be confirmed.

A foetal origin of PCOS has been proposed previously (Xita & Tsatsoulis 2006). Observations supporting this hypothesis include the findings that women with foetal androgen excess disorders such as congenital 21-hydroxylase deficiency and congenital adrenal virilising tumours develop PCOS features during their adult life (Hague et al. 1990, Barnes et al. 1994). Additionally, umbilical vein testosterone level in female foetuses of PCOS mothers is elevated to levels present in males (Barry et al. 2010), and pregnant PCOS women exhibit elevated serum levels of androgens (A₄, testosterone and DHEAS), and increased 3β-HSD1 but decreased placental aromatase enzyme activity, compared with pregnant non-PCOS women (Sir-Petermann et al. 2002, Maliqueo et al. 2013). These findings imply that female offspring of PCOS mothers are exposed to elevated levels of androgens. However, a large prospective cohort study did not find any relationship between maternal or umbilical cord androgen levels and the incidence of PCOS in adolescence (Hickey et al. 2009).
In summary, several findings from clinical observations and studies are consistent with, but cannot prove, a role for AR-mediated action in the aetiology of PCOS.

Insights into the role of AR-mediated actions in PCOS from androgen-induced PCOS animal studies

The origins and underlying mechanisms of PCOS remain unclear, and decisive clinical studies are limited by ethical and logistical constraints. Therefore, since the 1960s, increased androgen exposure has been used to induce characteristics of the human condition of PCOS in rodents, sheep and non-human primates (Table 2), and these models have been employed to study the origins and pathology of this disorder (reviewed in Walters et al. (2012b), Abbott et al. (2013) and Padmanabhan & Veiga-Lopez (2013)).

Androgen-induced rodent PCOS models

Testosterone

Prenatal. Testosterone treatment of rats during late gestation (days 16–19) induces the reproductive PCOS features of irregular oestrous cycles and an ovarian phenotype of increased preantral and antral follicle numbers, and decreased CL populations, indicative of oligo-ovulations, but the classic polycystic ovary phenotype is not present (Wu et al. 2010a). Treated rats also exhibited the endocrine PCOS-like traits of elevated testosterone and LH serum levels, and an increase in the frequency of LH pulse secretion (Foecking et al. 2005, Wu et al. 2010a). Both prenatal aromatisable (testosterone) and non-aromatisable (DHT) androgen exposure abolished an E2 benzoate-induced LH surge, implying that direct prenatal AR activation is involved in altering the GnRH/LH neurosecretory system (Foecking et al. 2005). On the other hand, in other studies, late gestational treatment of mice with testosterone (Keisler et al. 1991) or rats with TP (Swanson & Werff ten Bosch 1964, 1965, Fels & Bosch 1971, Huffman & Hendricks 1981, Slob et al. 1983, Tyndall et al. 2012) had no effect on cyclicity or ovarian function, inferred by the presence of follicles at various stages and CL. Variations in the observed phenotypes induced by prenatal treatment with testosterone or TP may be due to the degree of transplacental transfer of the administered steroid into the foetus (Fels & Bosch 1971). The timing of the prenatal androgen exposure may also play a role, as a previous study has identified that androgen exposure on gestational days 16–19 increases the number of preantral and antral follicles observed, while testosterone treatment on day 20 of gestation only had no effect on follicle populations (Ramezani et al. 2014). In addition, prenatal treatment with testosterone on days 16–19 of gestation in rats induced some metabolic PCOS features, including increased body weight and body fat, and elevated serum cholesterol and triglyceride levels, but no change in insulin sensitivity (Demissie et al. 2008).

Postnatal. Postnatal treatment of rats with TP during the first 6 days of life led to oligo- or anovulation, acyclicity, polycystic ovaries with atretic follicles and increased production of oestrogens (E1 and E2) and androgens (testosterone and A1) (Weisz & Lloyd 1965, McDonald & Doughty 1972, Ota et al. 1983, Pinilla et al. 1993, Kamijo et al. 1994). Similarly, mice treated in early postnatal life with TP or testosterone exhibited anovulation and the presence of polycystic ovaries (Edwards 1971, Kamijo et al. 1994, Tyndall et al. 2012). However, early postnatal treatment with TP did not cause the PCOS characteristics of LH hypersecretion (Pinilla et al. 1993, Tyndall et al. 2012). TP treatment for 35 consecutive days in pre-pubertal rats (~3 weeks of age) resulted in polycystic ovaries, anovulation and reduced follicle health (Beloosesky et al. 2004). Females also exhibited the metabolic PCOS characteristics of insulin resistance, indicating that androgens can induce insulin resistance (Beloosesky et al. 2004). Conversely, in another study using rats, TP treatment for 15–25 days did not induce a PCOS-like phenotype with females displaying morphologically normal ovaries (Tyndall et al. 2012). These findings highlight that androgenic effects involved in the development of the PCOS phenotype may only induce PCOS traits during specific time windows.

DHEA

Postnatal. Postnatal treatment of DHEA for 20 consecutive days in mice (Familiari et al. 1985, Sander et al. 2006, Lai et al. 2014) and rats (Ward et al. 1978, Lee et al. 1991, Anderson et al. 1992) induced some reproductive PCOS traits including acyclicity, polycystic ovaries and anovulation. Hyperandrogenism was present in this model (Familiari et al. 1985, Lee et al. 1991, Henmi et al. 2001, Lai et al. 2014), but conflict remains as to whether the feature of LH hypersecretion is present or not (Ward et al. 1978, Lee et al. 1991, Henmi et al. 2001). DHEA treatment for 20 days in mice did not affect body weight, glucose tolerance or cholesterol levels but did induce the metabolic PCOS traits of enlarged adipocytes, elevated serum fasting insulin levels and insulin resistance (Sander et al. 2006, Lai et al. 2014). In contrast to these studies, long-term (~13 weeks) exposure to DHEA induced no PCOS features in mature mice, indicating that the reported effects from short-term DHEA treatment in rodent models may be transient and may also indicate that DHEA is unlikely to cause/maintain PCOS features in women (Caldwell et al. 2014).

Dihydrotestosterone

Prenatal. Late gestational exposure of rats (days 16–19 of gestation) and mice (days 16–18 of gestation) to DHT did not induce the classic polycystic ovarian morphology in...
Table 2 Summary of the presence of human PCOS traits in adult rodent, sheep and primate PCOS models after treatment prenatally or postnatally with testosterone or DHT.

<table>
<thead>
<tr>
<th>Human diagnostic traits of PCOS</th>
<th>Rodents</th>
<th>Sheep</th>
<th>Primates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Irregular cycles/acyclicity</td>
<td>Yes&lt;sup&gt;a&lt;/sup&gt;/No&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Yes&lt;sup&gt;d,e,f,g&lt;/sup&gt;</td>
<td>Yes&lt;sup&gt;h&lt;/sup&gt;</td>
</tr>
<tr>
<td>Oligo- or anovulation</td>
<td>Yes&lt;sup&gt;a&lt;/sup&gt;/No&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Yes&lt;sup&gt;d,l&lt;/sup&gt;</td>
<td>Yes&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Hyperandrogenism († serum testosterone)</td>
<td>Yes&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Yes&lt;sup&gt;d&lt;/sup&gt;/No&lt;sup&gt;d&lt;/sup&gt;</td>
<td>–</td>
</tr>
<tr>
<td>LH hypersecretion</td>
<td>Yes&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Yes&lt;sup&gt;d&lt;/sup&gt;/No&lt;sup&gt;d&lt;/sup&gt;</td>
<td>–</td>
</tr>
<tr>
<td>Polycystic ovaries</td>
<td>No&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Yes&lt;sup&gt;d&lt;/sup&gt;/No&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Yes&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>↑ Ovary weight</td>
<td>No&lt;sup&gt;a&lt;/sup&gt;</td>
<td>No&lt;sup&gt;d&lt;/sup&gt;</td>
<td>–</td>
</tr>
<tr>
<td>↑ Numbers of preantral and/or antral follicles</td>
<td>Yes&lt;sup&gt;a&lt;/sup&gt;/No&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Yes&lt;sup&gt;d&lt;/sup&gt;/No&lt;sup&gt;d&lt;/sup&gt;</td>
<td>–</td>
</tr>
<tr>
<td>↓ Follicle health</td>
<td>–</td>
<td>Yes&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Yes&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>↑ Body fat</td>
<td>Yes&lt;sup&gt;b&lt;/sup&gt;</td>
<td>No&lt;sup&gt;d&lt;/sup&gt;</td>
<td>–</td>
</tr>
<tr>
<td>Adipocyte hypertrophy</td>
<td>Yes&lt;sup&gt;b&lt;/sup&gt;</td>
<td>No&lt;sup&gt;d&lt;/sup&gt;</td>
<td>–</td>
</tr>
<tr>
<td>Dyslipidaemia</td>
<td>Yes&lt;sup&gt;b&lt;/sup&gt;</td>
<td>No&lt;sup&gt;d&lt;/sup&gt;</td>
<td>–</td>
</tr>
<tr>
<td>Insulin resistance</td>
<td>No&lt;sup&gt;b&lt;/sup&gt;</td>
<td>No&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Yes&lt;sup&gt;i&lt;/sup&gt;</td>
</tr>
<tr>
<td>Presence of steatosis</td>
<td>Yes&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Yes&lt;sup&gt;d&lt;/sup&gt;</td>
<td>–</td>
</tr>
</tbody>
</table>

Yes, PCOS trait present; No, PCOS trait not present; Yes/No, conflicting findings; –, not determined in publication(s); GD, gestational day of treatment.

<sup>a</sup>Wu et al. (2010a), <sup>b</sup>Demissie et al. (2008), <sup>c</sup>Slob et al. (1983), <sup>d</sup>Caldwell et al. (2014), <sup>e</sup>Sullivan & Moenter (2004), <sup>f</sup>Moore et al. (2013), <sup>g</sup>Roland et al. (2010), <sup>h</sup>Beloosesky et al. (2004), <sup>i</sup>van Houten et al. (2012), <sup>j</sup>Manikkam et al. (2006), <sup>k</sup>Steckler et al. (2007), <sup>l</sup>Dumesic et al. (1997), <sup>m</sup>Abbott et al. (2005), <sup>n</sup>Abbott et al. (2013), <sup>o</sup>Hogg et al. (2011), <sup>p</sup>Eisner et al. (2002), <sup>q</sup>Sarma et al. (2005), <sup>r</sup>Veiga-Lopez et al. (2009), <sup>s</sup>West et al. (2001), <sup>t</sup>Smith et al. (2009), <sup>u</sup>Eisner et al. (2003), <sup>v</sup>Keller et al. (2014).
adult life but did lead to irregular oestrous cycles, altered follicular development, and reduced follicular health and ovulation rates, indicated by decreased CL numbers (Sullivan & Moenter, 2004, Wu et al., 2010a, Moore et al., 2013, Yan et al., 2013, Caldwell et al., 2014). Prenatal exposure to DHT also replicated the PCOS traits of androgen and LH hypersecretion, with rodents exhibiting increased testosterone and LH serum levels (Sullivan & Moenter, 2004, Wu et al., 2010a, Moore et al., 2013) and an increase in the frequency of LH pulse secretion (Wu et al., 2010a), in some but not all (Yan et al., 2013, Caldwell et al., 2014) rodent models. Importantly, the disruption in cycling and LH secretion appears to be mediated via the AR as treatment with flutamide restores oestrous cyclicity and GABAergic drive to GnRH neurons in female treated prenatally with DHT (Sullivan & Moenter, 2004). In addition, treatment of mice with DHT on days 16–18 of gestation did not alter body weight and/or fat mass, but it did induce some metabolic dysfunctions, including impaired glucose tolerance but normal insulin sensitivity and increased adipocyte size indicating altered adipocyte function (Roland et al., 2010, Caldwell et al., 2014). Additionally, in rats, prenatal exposure of DHT on days 16–19 of gestation induced an increase in body weight, hyperinsulinaemia and insulin resistance (Yan et al., 2013).

Postnatal. Early postnatal treatment (day 1 or 5) of rats with DHT propionate (DHTP, DHT ester with prolonged depot duration of action relative to DHT) had no effect upon cyclicity or ovarian morphology (McDonald & Doughty, 1972). In contrast, long-term treatment (>11 weeks) of DHT from ~3 weeks of age induces numerous reproductive and metabolic features of PCOS in rats and mice (Manneras et al., 2007, van Houten et al., 2012, Caldwell et al., 2014). Rats and mice displayed irregular oestrous cycles, oligo-ovulation and polycystic ovaries containing large atretic follicles with a thickened theca interna cell layer and a thin granulosa cell layer (Manneras et al., 2007, van Houten et al., 2012, Caldwell et al., 2014). DHT and 3α- and 3β-diol serum levels were elevated and P4 was significantly decreased, confirming the reduced ovulations rates, but LH and testosterone levels were unaltered (Manneras et al., 2007, Caldwell et al., 2014). Numerous metabolic traits of human PCOS are observed in DHT-treated rats and mice, including increased body weight, body fat, enlarged adipocytes, elevated leptin and cholesterol levels and increased presence of steatosis (Manneras et al., 2007, Johansson et al., 2010, Yanes et al., 2011, van Houten et al., 2012). DHT-treated rats displayed insulin resistance, while mice did not (Caldwell et al., 2014), but they did exhibit glucose intolerance (van Houten et al., 2012).

Overall, these findings imply that androgens play a role in the pathogenesis of PCOS, but animal models that use testosterone or DHEA to induce PCOS features are not ideal when trying to define AR-regulated mechanisms, as steroid effects may be induced by AR and/or ER, because testosterone or DHEA can be converted into steroids with the potential to exert ER-mediated effects. DHT is a non-aromatisable pure androgen that activates only AR signalling, thus making it the preferred androgen to decipher the true role of AR-mediated actions in the development of PCOS. Prenatal exposure with DHT induced irregular reproductive cycles and reduced ovulations, directly implicating abnormal AR signalling in the mechanisms leading to disrupted regulation of the hpg axis in PCOS patients. Postnatal DHT treatment from 3 weeks of age replicated a breadth of human PCOS traits including anovulation, acyclicity, polycystic ovaries, obesity, adipocyte hypertrophy and dyslipidaemia. Collectively, these findings strongly support a direct role for AR-mediated actions in the development of reproductive, endocrine and metabolic PCOS features.

Androgen-induced sheep PCOS models

Testosterone

Prenatal. Excess prenatal exposure to testosterone or TP leads to irregular cycling and oligo- or anovulation in adult ewes (Clarke et al., 1976), with the severity of disruption higher in females treated earlier in gestation (days 30–80), than in those exposed later (Clarke et al., 1977, Savabieasfahani et al., 2005). Prenatal treatment with testosterone or TP in ewes between the days of 30–90 of gestation induces the PCOS ovarian characteristics of increased ovarian weight (West et al., 2001, Forsdike et al., 2007), polycystic ovaries (West et al., 2001, Forsdike et al., 2007), increased follicular recruitment (Clarke et al., 1977, West et al., 2001, Smith et al., 2009) and increased presence of large antral follicles (Manikkam et al., 2006, Steckler et al., 2007). However, other studies failed to observe an increase in ovarian weight (Smith et al., 2009, Hogg et al., 2012) and numbers of growing follicles (preantral and/or antral) (Hogg et al., 2012). The endocrine PCOS feature of LH excess has also been observed in some (Sarma et al., 2005, Savabieasfahani et al., 2005) but not all (West et al., 2001, Hogg et al., 2012) female ewes prenatally exposed to testosterone or TP. Moreover, while prenatal testosterone treatment was found to selectively increase granulosa cell AR expression in antral follicles (Ortega et al., 2009), suggesting increased AR activity; the predominant PCOS feature of hyperandrogenism has not been observed, with serum testosterone levels similar to that of control females (Hogg et al., 2012).

Female sheep prenatally exposed to testosterone or TP on days 30–90 of gestation have been reported to exhibit some metabolic characteristics of PCOS, including reduced insulin sensitivity (Recabarren et al., 2005, Padmanabhan et al., 2010), elevated plasma free fatty acids (Veiga-Lopez et al., 2013), hypertension (King et al., 2007) and hepatic steatosis (Hogg et al., 2011). However, conflicting findings are present with one study finding that prenatal exposure to excess testosterone can increase, rather than decrease, insulin sensitivity.
Dihydrotestosterone

Prenatal. Few studies are available on the ovine PCOS model, where ewes have been treated prenatally with DHT, rather than testosterone or TP. The key PCOS characteristics of cycle irregularity and ovulation disruption (Steckler et al. 2007) have been reported in ewes prenatally exposed to excess DHT on days 30–90 of gestation, but features such as the classic polycystic ovary appearance (Smith et al. 2009) and increased ovarian weight (West et al. 2001) are not displayed. Interestingly, while prenatal testosterone exposure increased the number of large antral follicles and follicular persistence in one study, prenatal DHT exposure only increased the number of small growing follicles, but not the number of large antral follicles (Steckler et al. 2007). Furthermore, in another study, while prenatal testosterone was found to increase follicle recruitment, prenatal DHT did not do so (Smith et al. 2009). These findings imply that both androgenic and oestrogenic mechanisms are involved in the altered follicular dynamics within PCOS ovaries. In addition, there is disagreement on whether prenatal exposure to DHT can induce the endocrine PCOS feature of LH hypersecretion, with studies reporting both a significant increase (Veiga-Lopez et al. 2009) and no change in LH levels (West et al. 2001). At present, there are limited data available on whether prenatal DHT treatment can induce metabolic disturbances associated with PCOS. However, at 11 weeks of age, females treated prenatally with DHT exhibited a body weight similar to control females, but reduced insulin sensitivity (Padmanabhan et al. 2010).

In summary, prenatal exposure with testosterone and TP in sheep can mimic several features of the reproductive and metabolic phenotypes of human PCOS, with prenatally testosterone-treated ewes exhibiting acyclicity, disrupted ovulations, polycystic ovaries, insulin resistance, hypertension and hepatic steatosis. While there are some inconsistencies in the findings between models, on the whole these findings suggest that excess levels of androgens, via either direct or indirect actions, are involved in the manifestation of both the PCOS ovarian phenotype and altered metabolic function. Less data are available on the effects of prenatal DHT treatment in ewes. However, it has been reported to cause the PCOS features of irregular cycles, LH hypersecretion and the stimulation of early-stage follicle growth, indicating that direct AR actions play a role in the altered endocrine patterns of follicle development observed in PCOS.

Androgen-induced primate PCOS models

Testosterone

Prenatal. Adult female rhesus monkeys exposed to excess TP during early–mid-gestation (treated for 15–40 days between days 40–80 of gestation) or late gestation (treated for 15–25 days between days 94–140 of gestation) have been reported to fulfil the diagnostic criteria for PCOS in women by exhibiting irregular cycles, polycystic ovaries and/or hyperandrogenism (Dumesic et al. 1997, Eisner et al. 2002, Abbott et al. 2005, 2013). The endocrine PCOS characteristic of LH hypersecretion is present in females exposed to TP during early–mid-gestation, but not in those exposed during late gestation (Dumesic et al. 1997, 2002, Abbott et al. 2005). Furthermore, many PCOS metabolic traits are also present in female monkeys exposed to TP during early–mid-gestation, including increased abdominal adiposity, hyperlipidaemia, hyperglycaemia, impaired pancreatic β-cell function, insulin resistance and type 2 diabetes (Eisner et al. 2003, Abbott et al. 2005, 2009, 2013, Keller et al. 2014). Females androgenised during late gestation displayed fewer metabolic traits, with only impaired glucose tolerance and increased abdominal fat reported (Abbott et al. 2005).

Postnatal. Treatment of rhesus monkeys with testosterone within 24 h of birth induced no obvious defects in menstrual cyclicity or ovarian morphology (Trelloar et al. 1972). Similarly, testosterone treatment for 50 days after birth had no effect on ovulation in female marmoset monkeys (Abbott & Hearn 1978). Testosterone treatment in pre-pubertal female rhesus monkeys also had no effect on ovulation rates or ovarian morphology, but did lead to an increase in LH pulse frequency in early adulthood (McGee et al. 2012). Exposure of an adult female rhesus monkey to high doses of testosterone for 3–10 days causes enhanced ovarian follicle recruitment and induced ovarian phenotype of numerous small-to-medium-sized antral follicles without increasing levels of follicular atresia (Vendola et al. 1998, 1999a). However, exposure to testosterone for a longer period of time (13–16 months) caused no difference in follicle populations (Faiman et al. 1988). Additionally, while pre-pubertal testosterone treatment led to increased body weight by early adulthood, there was no change in overall per cent body fat, insulin sensitivity or glucose tolerance (McGee et al. 2012). Similarly, chronic testosterone exposure in adult female rhesus monkeys for up to 4 and a half years did not cause any insulin resistance or glucose intolerance (Billiar et al. 1987).

Dihydrotestosterone

Prenatal. DHT exposure on days 40–45 of gestation (early gestation) for 55–70 consecutive days caused adolescent onset of irregular menstrual cycles (Abbott et al. 2013); however, other reproductive and metabolic PCOS traits have not been assessed at present.
Postnatal. As observed for testosterone, exposure of adult female rhesus monkeys to high doses of DHT for 3–10 days stimulated ovarian follicle recruitment and increased numbers of growing preantral and small antral follicles, implying that these actions are mediated directly via the AR (Vendola et al. 1998, 1999a).

In summary, the PCOS phenotype is closely mimicked by in utero exposure of rhesus monkeys to excess levels of testosterone, with females exhibiting a wide range of reproductive, hormonal and metabolic PCOS traits. Little data are available on the phenotype of females exposed prenatally to DHT; therefore, it is difficult to decipher the specific role of direct AR-mediated mechanisms. However, postnatal treatment with both testosterone and DHT stimulates follicle recruitment and follicle development, and provides evidence to support a role for AR signalling the development of the ovarian phenotype of increased numbers of growing follicles.

In conclusion, rodent, sheep and primate animal PCOS models induced by androgen excess have advanced our understanding of the pathogenesis of PCOS and strongly support a role for androgen and AR-mediated actions in the aetiology of this disorder. The comparison of aromatisable (testosterone, TP) and non-aromatisable (DHT) androgens in the induction of PCOS animal models has allowed for an insight into the PCOS traits, which are programmed via AR- vs ER-mediated actions. The majority of studies allowing for comparison of testosterone and DHT have been conducted in rodents and demonstrate that non-aromatisable androgen DHT can induce the key diagnostic criteria of irregular cycles, disrupted ovulations and hyperandrogenism, as well as many metabolic PCOS characteristics. However, when interpreting findings, it should be noted that DHT can be converted into 3β-diol, which has the potential to elicit ER-mediated effects. Furthermore, it is clear that both androgenic and oestrogenic mechanisms are involved in the programming of the PCOS phenotype as in the prenatally androgenised sheep model testosterone, but DHT does not induce polycystic ovaries and abnormal antral follicle morphology and does not increase follicle activation (West et al. 2001, Smith et al. 2009). In saying this, further support for AR-mediated actions playing a predominant role in the manifestation of PCOS traits comes from the findings that exposure of rats to E2 valerate can induce anovulation and polycystic ovaries, but it fails to provoke the breadth of features induced by androgens including LH hypersecretion, hyperandrogenism, obesity and alterations in glucose and insulin sensitivity (Brawer et al. 1978, Stener-Victorin et al. 2005). Furthermore, differences in the timing of the elevated androgen exposure have recently been put forward as a key determinant in the development of various characteristics of PCOS.

Androgen–AR-mediated molecular mechanisms controlling ovarian traits of PCOS

The ovarian phenotype of PCOS is characterised by polycystic ovaries, disordered follicle development, ovarian enlargement, thickened outer tunica albuginea and increased density and area of stroma (Franks 1995, Chang 2007, Franks et al. 2008). However, the underlying molecular mechanism leading to these altered ovarian features remains unclear. IGFs are survival factors shown to stimulate follicle development (Walters et al. 2006). Elevated IGF activity is proposed as a mechanism leading to increased activation and accelerated growth of early-stage follicles within PCOS ovaries. IGFR1 mRNA and protein expressions are elevated in anovulatory polycystic ovaries (Stubb et al. 2013), and testosterone or DHT increases IGF1 and IGF1R mRNA in primate ovaries (Vendola et al. 1999a,b), suggesting that hyperandrogenism, a key feature of PCOS, may induce accelerated follicle growth via upregulation of IGF actions. Similarly, hyperandrogenism in PCOS may also promote primordial follicle activation through the PI3K/Akt/Foxo3a pathway, as testosterone stimulates activation of primordial follicles by inducing Foxo3a phosphorylation and activating PI3K/Akt signalling via non-genomic mechanisms (Yang et al. 2010). AR-mediated androgen actions are also implicated in the follicular arrest observed in PCOS ovaries. Androgen excess is reported to reduce Cx43 expression in human granulosa cells, with the suppression blocked by addition of flutamide. Thus, it has been proposed that hyperandrogenism in PCOS patients may impair communication between granulosa cells leading to follicle development dysfunction and ovulatory dysfunction (Wu et al. 2010b). Additionally, GDF9 expression, an oocyte-derived growth factor, which is essential for ovarian follicular development (Dong et al. 1996), is reduced in the oocytes of women with PCOS (Teixeira Filho et al. 2002). Treatment of mouse ovaries with testosterone also reduces GDF9 expression (Yang et al. 2010), suggesting that elevated androgen levels may downregulate GDF9 expression and cause follicular arrest. Furthermore, recent studies have implicated the actions of chemerin and its receptor, chemokine-like receptor (CMKLR1), in the antral follicle growth arrest observed in polycystic ovaries. In a DHT-treated rat PCOS model, chemerin and CMKLR1 expressions are elevated, and in vitro, chemerin treatment suppressed basal, FSH- and GDF9-stimulated follicle growth, FSH-induced follicular steroidogenesis and induced granulosa cell apoptosis (Wang et al. 2012, Kim et al. 2013).

Perturbation of the epigenome by disrupted DNA methylation is another mechanism that is proposed as a possible origin for the development of PCOS. Epigenetic alterations have been identified in a prenatally androgenised primate PCOS model, implying that an increased predisposition to PCOS may be induced by
excess foetal androgen exposure altering the epigenome (Xu et al. 2011). In particular, the most significantly differentially methylated genes identified were involved in transforming growth factor beta (TGFβ) signalling, which has been implicated in the aetiology of PCOS (Raja-Khan et al. 2014). It is clear that PCOS ovaries exhibit gene dysregulation (Diao et al. 2004). A possible role for altered miRNA levels as a mode of action for altered gene expression involved in the pathophysiology of PCOS has been suggested (Sorensen et al. 2014). Recent data has implicated (or proposes) androgens in the alteration of post-transcription regulation of gene expression, as dysregulation of ovarian miRNA expression has been identified in a DHT-induced rat PCOS model (Hossain et al. 2013). However, our understanding of a potential role for miRNAs in PCOS is limited.

In summary, the mechanisms underlying the development of the PCOS ovarian phenotype still remain poorly understood. In recent years, in vitro studies and in vivo animal models have identified several intra-ovarian pathways, which are responsive to elevated androgen exposure, providing various possible pathways for AR-mediated androgen actions in fulfilling a key role in the development of the polycystic ovarian phenotype.

**Human implications for PCOS from clinical and animal studies of AR-mediated actions**

Despite PCOS being one of the most common endocrine conditions in women, and various proposed hypotheses, the aetiology of PCOS remains unknown. As a result, curative treatments are lacking and optimal management via manipulation of causative pathways, rather than symptomatic measures, remain yet to be identified. Elevation of androgen exposure in humans (Hague et al. 1990, Pache & Fauser 1993) and animal PCOS models (Table 2) causes the development of polycystic ovaries, suggesting that androgen excess per se can initiate ovarian features of PCOS. Furthermore, while none of the animal PCOS models created to date display all of the human characteristics of PCOS, elevated androgen exposure in a range of mammalian species (mouse, rat, sheep and primate) can induce most of the spectra of reproductive, endocrine and metabolic features of human PCOS (Table 2), strongly supporting a role for androgens in the pathogenesis of PCOS. Future analysis should focus on a better parsing of the roles of androgenic (mediated via AR) vs oestrogenic (mediated via ER) mechanisms in the features of PCOS, using AR antagonists and comparison of experimental models of mature animals created by administration of aromatisable vs non-aromatisable androgens or inducing aromatase inhibition. One such study has been published, reporting that postnatal treatment of prenatally testosterone-exposed females with the androgen antagonist flutamide increased the total LH surge response to E2 positive feedback challenge. These findings support the use of androgen antagonists to improve ovulation rates in PCOS patients (Abi et al. 2012). In addition, the most significant findings on specific genes discovered from GWAS or similar hypothesis-free studies involved in the development of PCOS, and the functionality of specific genes in the PCOS environment, may be revealed by the use of gene knock in/out mouse models in combination with a mouse PCOS model. These novel approaches will have great promise to enhance our understanding of the mechanisms underlying the development of PCOS and, in the future, may lead to the development of novel and evidence-based treatments for this disorder based on its pathogenic mechanisms.

**Conclusions**

There is now substantial evidence supporting an important role for direct AR-mediated androgen actions in follicle growth and health, ovarian function, and the development and/or maintenance of human PCOS. AR-mediated actions play an important role in optimising follicle development and ovulation. Studies have revealed that AR can act on ovarian follicle development from initiation of primordial follicles right through to ovulatory processes, and its actions are important in stimulating follicle growth and the maintenance of follicle/oocyte health and embryo viability. Granulosa cells have been identified as a crucial site for AR-mediated actions, however, it is clear that AR-regulated neuroendocrine control also plays a role in the regulation of normal ovarian function. It is now apparent that optimal levels of androgenic actions are required for normal ovarian function, with reduced levels, as observed in the ARKO models, leading to sub-fertility, while androgen excess has a negative effect on ovulation rates and is the most consistent feature of PCOS. Numerous androgen-induced PCOS animal models have confirmed that elevated androgen exposure can replicate many PCOS features. In particular, these animal models have identified that elevated androgen levels can dysregulate the intra-ovarian expression of key factors and processes involved in normal follicle development.

In conclusion, by combining clinical observations with judiciously selected and well-designed animal models, informative information on the specific AR-mediated mechanisms regulating female fertility and the development of PCOS is being revealed, with the hope that, in the future, elucidation of the role of androgens in female reproduction will translate into treatment that will assist in improving ovarian response and ART outcomes, and allow for the development of novel and evidence-based treatments for PCOS.
Declaration of interest

The author declares that there is no conflict of interest that could be perceived as prejudicing the impartiality of the review.

Funding

This work carried out by K A Walters and colleagues was supported by the Australian National Health and Medical Research Council project grants (632678, APP1022648) and the Australian Research Council Discovery Early Career Research Award (DE120100796).

References


Baculescu N 2013 The role of androgen receptor activity mediated by the CAG repeat polymorphism in the pathogenesis of PCOS. Journal of Medicine and Life 6 18–25.


Cardenas H & Pope WF 1994 Administration of testosterone during the follicular phase increased the number of corpora lutea in gilts. Journal of Animal Science 72 2930–2935.


Cattaneo-Jonard S, Jamieson SP, Leclerc A, Gonesa J, Dewally D & di Clemente N 2008 Anti-Mullerian hormone, its receptor, FSH receptor, and androgen receptor genes are overexpressed by granulosa cells from stimulated follicles in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 93 4456–4461. (doi:10.1210/jcem.2008-1231)
null


Kuhn R & Torres RM 2010 Androgen receptor epigenetic variations influence mouse follicle culture bioassay that encompasses most stages of follicular development. Endocrinology 154 1519–1527. (doi:10.1210/en.2010-0035)


Lyons MF & Glenister PH 1974 Evidence from Tfm-O that androgen is inessential for reproduction in female mice. Nature 246 366–367. (doi:10.1038/247366a0)


Nielsen ME, Rasmussen IA, Kristensen SG, Christensen ST, Mollgard K, Wrelford AE, Byskov AG & Yding AC 2011 In human granulosa cells from small antral follicles, androgen receptor mRNA and androgen levels in follicular fluid correlate with FSH receptor mRNA. Molecular Human Reproduction 17 63–70. (doi:10.1093/molehr/gat073)


www.reproduction-online.org


R216 K A Walters


www.reproduction-online.org


Salvetti NR, Aifaró NS, Velazquez MM, Amweg AN, Matiller V, Diaz PU & Ortega HH 2012 Alteration in localization of steroid hormone receptors and coregulatory proteins in follicles from cows with induced ovarian follicular cysts. Reproduction 144 723–735. (doi:10.1530/REP-12-0188)


Sen A & Hammes SR 2010 Granulosa cell-specific androgen receptors are critical regulators of ovarian development and function. Molecular Endocrinology 24 1393–1403. (doi:10.1210/me.2010-0006)


Walters KA, Allan CM, Jimenez M, Lim PR, Davey RA, Zajac JD, Illingworth P & Handelsman DJ 2007 Female mice hipoalinsufficient for an activated androgen receptor (AR) exhibit age-dependent defects that resemble the AR null phenotype of dysfunctional late follicle development, ovulation, and fertility. *Endocrinology* 148 3674–3684. (doi:10.1210/endo-2007-0248)


Wu YG, Bennett J, Talla D & Stocco C 2011 Testosterone, not 5α-dihydrotestosterone, stimulates LH-R1 leading to FSH-independent expression of Cyp19 and P450scc in granulosa cells. Molecular Endocrinology 25 656–668. (doi:10.1210/me.2010-0367)


